New Perspective on Type 2 Diabetes, Dyslipidemia and Non-alcoholic Fatty Liver Disease

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2020 Apr 2

PMID 32232972

Citations 16

Authors

Takashi Matsuzaka

Hitoshi Shimano

Affiliations

Soon will be listed here.

Abstract

Serum lipid abnormalities (dyslipidemias) are major risk factors for cardiovascular disease in type 2 diabetes mellitus. Recent findings provide new evidence that dyslipidemia characterized by elevated triglycerides and non-high-density lipoprotein cholesterol levels with a decreased high-density lipoprotein cholesterol level are risk factors for cardiovascular disease in patients with type 2 diabetes. There are multiple therapeutic agents to help patients to achieve target lipid levels, but understanding the molecular mechanisms could provide useful information for new treatment strategies for diabetic dyslipidemia.

Citing Articles

Association between the triglyceride to high-density lipoprotein cholesterol ratio and type 2 diabetes mellitus in non-alcoholic fatty liver disease.

Bian L, Tang T, Yu Q, Tong X, Hu S, You Y Sci Rep. 2024; 14(1):31048.

PMID: 39730877 PMC: 11680680. DOI: 10.1038/s41598-024-82116-0.

Hepatic and metabolic outcomes induced by sub-chronic exposure to polystyrene microplastics in mice.

Lee S, Lin T, Yan Y, Chien C, Cheng T Arch Toxicol. 2024; 98(11):3811-3823.

PMID: 39183192 DOI: 10.1007/s00204-024-03847-7.

"Adjusting internal organs and dredging channelon" electroacupuncture glycolipid metabolism disorders in NAFLD mice by mediating the AMPK/ACC signaling pathway.

Jia X, Li M, Zhang W, Guo Y, Xue F, Ma S Diabetol Metab Syndr. 2024; 16(1):173.

PMID: 39054547 PMC: 11271196. DOI: 10.1186/s13098-024-01416-7.

Daraesoon (shoot of hardy kiwi) mitigates hyperglycemia in db/db mice by alleviating insulin resistance and inflammation.

Choi H, Kim J Nutr Res Pract. 2024; 18(1):88-97.

PMID: 38352218 PMC: 10861346. DOI: 10.4162/nrp.2024.18.1.88.

The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry.

Alorfi N, Ashour A Diabetes Metab Syndr Obes. 2023; 16:3115-3121.

PMID: 37822800 PMC: 10564080. DOI: 10.2147/DMSO.S430740.

References

Kimura K, Inaba Y, Watanabe H, Matsukawa T, Matsumoto M, Inoue H . Nicotinic alpha-7 acetylcholine receptor deficiency exacerbates hepatic inflammation and fibrosis in a mouse model of non-alcoholic steatohepatitis. J Diabetes Investig. 2018; 10(3):659-666. PMC: 6497582. DOI: 10.1111/jdi.12964. View

Hong B, Liu J, Zheng J, Ke W, Huang Z, Wan X . Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients. J Diabetes Investig. 2017; 9(4):952-958. PMC: 6031491. DOI: 10.1111/jdi.12792. View

Jing Y, Sun Q, Xiong X, Meng R, Tang S, Cao S . Hepatocyte growth factor alleviates hepatic insulin resistance and lipid accumulation in high-fat diet-fed mice. J Diabetes Investig. 2018; 10(2):251-260. PMC: 6400203. DOI: 10.1111/jdi.12904. View

Wang X, Yang Z, Xue B, Shi H . Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology. 2011; 152(3):836-46. PMC: 3040050. DOI: 10.1210/en.2010-0855. View

Miyamoto T, Matsuzaka T, Shimano H . Rho-associated, coiled-coil-containing protein kinase 1 as a new player in the regulation of hepatic lipogenesis. J Diabetes Investig. 2019; 10(5):1165-1167. PMC: 6717821. DOI: 10.1111/jdi.13051. View

Ferguson A, Roy S, Kormanik K, Kim Y, Dumas K, Ritov V . TATN-1 mutations reveal a novel role for tyrosine as a metabolic signal that influences developmental decisions and longevity in Caenorhabditis elegans. PLoS Genet. 2014; 9(12):e1004020. PMC: 3868569. DOI: 10.1371/journal.pgen.1004020. View

Hong M, Ling Y, Lu Z, Liu Y, Gu P, Shao J . Contribution and interaction of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and triglyceride to diabetes in hypertensive patients: A cross-sectional study. J Diabetes Investig. 2018; 10(1):131-138. PMC: 6319496. DOI: 10.1111/jdi.12856. View

Li J, Cao Y, Sun X, Han L, Li S, Gu W . Plasma tyrosine and its interaction with low high-density lipoprotein cholesterol and the risk of type 2 diabetes mellitus in Chinese. J Diabetes Investig. 2018; 10(2):491-498. PMC: 6400201. DOI: 10.1111/jdi.12898. View

Huang H, Lee S, Sousa-Lima I, Kim S, Hwang W, Dagon Y . Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest. 2018; 128(12):5335-5350. PMC: 6264719. DOI: 10.1172/JCI63562. View

10.

Goto M, Furuta S, Yamashita S, Hashimoto H, Yano W, Inoue N . Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport. J Diabetes Investig. 2018; 9(6):1261-1269. PMC: 6215941. DOI: 10.1111/jdi.12860. View

11.

Lee Y, Lee S, Lee C, Kim S, Song Y, Yoon M . Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. Sci Rep. 2016; 6:24013. PMC: 4820743. DOI: 10.1038/srep24013. View

12.

Dai J, Yi J, Zhang S, Chen P, Jin H, Yu X . Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals. J Diabetes Investig. 2018; 10(3):793-800. PMC: 6497611. DOI: 10.1111/jdi.12963. View

13.

Kurozumi A, Okada Y, Arao T, Kobayashi T, Masuda D, Yamashita S . Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. J Diabetes Investig. 2017; 9(2):360-365. PMC: 5835469. DOI: 10.1111/jdi.12739. View

14.

Liu L, Li Q, Yuan Z, Zhao M, Zhang X, Zhang H . Non-high-density lipoprotein cholesterol is more informative than traditional cholesterol indices in predicting diabetes risk for women with normal glucose tolerance. J Diabetes Investig. 2018; 9(6):1304-1311. PMC: 6215933. DOI: 10.1111/jdi.12837. View